Overview

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Status:
Completed

Trial end date:
2021-05-19

Target enrollment:

Participant gender:

Summary

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Antibodies, Monoclonal